TAK — Takeda Pharmaceutical Company Limited

Summary of Takeda's Q2 FY 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: JPY 2.2 trillion, down 6.9% YoY (down 3.9% at constant exchange rates).
• Core Operating Profit: JPY 639.2 billion, a decline of 11.2% YoY (8.8% at CER).
• Reported Operating Profit: JPY 253.6 billion, down 27.7% YoY due to higher impairment losses.
• Core EPS: JPY 279; Reported EPS: JPY 72, reflecting a 40% decline in net profit due to a non-deductible impairment loss.
• Free Cash Flow: Strong at JPY 525.4 billion, aided by improved working capital.

2. Strategic Updates and Business Highlights

• Product Growth: Launch products grew 5.3% at CER, with expectations for acceleration in H2.
• ENTYVIO: Growth slowed; revised full-year forecast to 6% at CER due to competitive pressures and slower pen conversion.
• Oncology Pipeline: Positive Phase III results for rusfertide and oveporexton; partnership with Innovent Biologics to enhance oncology portfolio with three new assets.
• Operational Efficiency: Continued focus on cost control and operational efficiencies, including a restructuring plan impacting 600 positions.

3. Forward Guidance and Outlook

• Updated Guidance: Total revenue expected to remain broadly flat YoY; core operating profit and EPS guidance revised to low single-digit percentage declines due to transactional FX impacts.
• Dividend Outlook: Maintained at JPY 200 per share for the full year.
• Future Growth: Anticipation of a new business cycle post-VYVANSE generic impact, with potential new product launches and pipeline advancements.

4. Bad News, Challenges, or Points of Concern

• VYVANSE Impact: Significant revenue loss (approx. JPY 100 billion) due to loss of exclusivity, with expectations of continued decline.
• Transactional FX Headwinds: Euro appreciation negatively impacting profits and product costs, particularly for QDENGA.
• Competitive Pressures: Increased competition affecting ENTYVIO growth, particularly in Crohn's disease (CD) and challenges in expanding access to the ENTYVIO Pen.
• Impairment Losses: Higher impairment losses from discontinued cell therapy efforts affecting reported profits.

5. Notable Q&A Insights

• ENTYVIO Access: Ongoing efforts to improve insurance coverage and local market access, with expectations for growth acceleration as hurdles are resolved.
• Innovent Partnership Concerns: Questions raised about R&D costs and the ability to replicate positive data from China in international trials; Takeda remains confident in their due diligence.
• Celiac Disease Programs: Takeda is optimistic about ongoing Phase II studies, with potential for significant market impact if successful.
• PDT Business: Focus on improving efficiency rather than expanding collection centers; confident in achieving high single-digit growth for albumin despite market challenges in China.

Overall, Takeda's Q2 FY 2025 results reflect a challenging environment primarily due to the impact of VYVANSE generics and currency fluctuations, but the company is strategically positioned for future growth through pipeline advancements and operational efficiencies.